NCT00505739View on ClinicalTrials.gov

Mifepristone for Patients With Endometrial Cancer and LGESS

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

October 31, 2007

Study Completion Date

May 31, 2008

Conditions
Endometrial Cancer
Interventions
DRUG

Mifepristone

200 mg by mouth (PO) Daily x 4 Weeks

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00505739 - Mifepristone for Patients With Endometrial Cancer and LGESS | Biotech Hunter | Biotech Hunter